SpeeDx have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the SARS-CoV-2 Delta variant of concern (VOC), P681R. The recently launched PlexPrime® SARS-CoV-2...
SpeeDx Pty. Ltd. announced today their PlexPCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from a database of over 1,000,000 sequences, the two gene, single-well...
SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its PlexPCR® SARS-CoV-2* assay – a two gene test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the...
Roche customers will now have even more opportunities to utilise ResistancePlus® tests to support clinically important treatment decisions. SpeeDx ResistancePlus® MG and ResistancePlus® GC are now validated for cobas z...
Syphilis remains an important public health concern due to global case increases. In Australia, the largest syphilis outbreak ever recorded has been ongoing for the last 10 years, and now...
SpeeDx have partnered with researchers from Nepean Hospital in an exclusive agreement to commercialise a molecular test for IFI27 - a host biomarker with expression strongly correlated with disease progression...
The opening of a PC2 laboratory facility at SpeeDx Sydney headquarters is an exciting milestone to celebrate. SpeeDx performs all commercial functions including research, development and manufacturing out of their...
Important clinical data published in Clinical Infectious Diseases demonstrated practical effectiveness of Resistance Guided Therapy for treating gonorrhoea. Led by Dr. Jeffrey Klausner, Professor of epidemiology and medicine at UCLA,...
Important data using ResistancePlus® MG to investigate over 1500 symptomatic vaginitis patients. Mycoplasma genitalium (Mgen) infection was more prevalent in women with bacterial vaginosis (BV) (7.0% Mgen positive) compared with...
Mycoplasma genitalium (Mgen) infections treated using resistance guided therapy led to high cure rates and low levels of de novo resistance, according to latest data from Melbourne Sexual Health published...
